Imperial College Healthcare NHS Trust, which has one of the largest cellular pathology workloads in the UK, has chosen Leica Microsystems’ BOND platform to provide staining capabilities across its three hospitals.
The Trust has installed a total of 10 new Leica BOND systems (pictured), which offer increased throughput and improved staining consistency.
The BOND family is well established as a platform for cellular and tissue analysis in medical pathology, combining sensitivity and productivity.
“Following a comprehensive tender process, Leica Biosystems was able to offer the best solution for our needs, combining good staining quality with high throughput,” said Donna Horncastle, Laboratory Manager for Cellular Pathology at Hammersmith Hospital.
“We have been very impressed with the staining quality of the platforms. These systems also offer considerable efficiency savings – allowing staff time to be used more effectively – and we no longer rely on batch processing of samples, therefore improving turnaround times and streamlining our workflow.”
Chris Rhoades, Leica’s Global Product Manager for BOND Instrumentation, commented: “We are thrilled to have been chosen by Imperial College NHS Trust and look forward to working with them in the continued delivery of cost-effective and efficient clinical and research services.”
Based in Germany, Leica Microsystems is a leading global provider of scientific instruments. The company’s Biosystems Division, also known as Leica Biosystems, supplies histopathology laboratories with an extensive range of products.